Vaccine candidate against COVID-19
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | DNA |
| Clinical data | |
| Routes of administration | Intramuscular, Intradermal[1] |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
|
Medical response |
|
 COVID-19 portal |
AG0302-COVID-19 is a COVID-19 vaccine candidate developed by AnGes Inc.[2][3] This candidate followed a previous one called AG0301-COVID-19.[4]
References
- ^ "Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose)". clinicaltrials.gov. United States National Library of Medicine. Archived from the original on 9 August 2021. Retrieved 6 October 2021.
- ^ "Study of COVID-19 DNA Vaccine (AG0302-COVID19)". clinicaltrials.gov. United States National Library of Medicine. 3 December 2020. Retrieved 11 March 2021.
- ^ "Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)". clinicaltrials.gov. United States National Library of Medicine. Archived from the original on 8 December 2020. Retrieved 11 March 2021.
- ^ "Study of COVID-19 DNA Vaccine (AG0301-COVID19)". ClinicalTrials.gov. United States National Library of Medicine. 9 July 2020. NCT04463472. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
Scholia has a profile for AG0302-COVID‑19 (Q106514993).
| Development | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
 | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 20 April 2024, at 05:33